FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3217437563> ?p ?o ?g. }

• W3217437563 endingPage "e2134427" @default.
• W3217437563 startingPage "e2134427" @default.
• W3217437563 abstract "<h3>Importance</h3> Benign prostatic hyperplasia (BPH) in older men can cause lower urinary tract symptoms (LUTS), which are increasingly managed with medications. Frailty may contribute to both symptom progression and serious adverse events (SAEs), shifting the balance of benefits and harms of drug therapy. <h3>Objective</h3> To assess the association between a deficit accumulation frailty index and clinical BPH progression or SAE. <h3>Design, Setting, and Participants</h3> This cohort study used data from the Medical Therapy of Prostatic Symptoms trial, which compared placebo, doxazosin, finasteride, and combination therapy in men with moderate-to-severe LUTS, reduced urinary flow rate, and no prior BPH interventions, hypotension, or elevated prostate-specific antigen. Enrollment was from 1995 to 1998, and follow-up was through 2001. Data were assessed in February 2021. <h3>Exposures</h3> A frailty index (score range, 0-1) using 68 potential deficits collected at baseline was used to categorized men as robust (score ≤0.1), prefrail (score 0.1 to <0.25), or frail (score ≥0.25). <h3>Main Outcomes and Measures</h3> Primary outcomes were time to clinical BPH progression and time to SAE, as defined in the parent trial. Adjusted hazard ratios (AHRs) were estimated using Cox proportional hazards regressions adjusted for demographic variables, treatment group, measures of obstruction, and comorbidities. <h3>Results</h3> Among 3047 men (mean [SD] age, 62.6 [7.3] years; range, 50-89 years) in this analysis, 745 (24%) were robust, 1824 (60%) were prefrail, and 478 (16%) were frail at baseline. Compared with robust men, frail men were older (age ≥75 years, 12 men [2%] vs 62 men [13%]), less likely to be White (646 men [87%] vs 344 men [72%]), less likely to be married (599 men [80%] vs 342 men [72%]), and less likely to have 16 years or more of education (471 men [63%] vs 150 men [31%]). During mean (SD) follow-up of 4.0 (1.5) years, the incidence rate of clinical BPH progression was 2.2 events per 100 person-years among robust men, 2.9 events per 100 person-years among prefrail men (AHR, 1.36; 95% CI, 1.02-1.83), and 4.0 events per 100 person-years among frail men (AHR, 1.82; 95% CI, 1.24-2.67; linear<i>P</i> = .005). Larger point estimates were seen among men who received doxazosin or combination therapy, although the test for interaction between frailty index and treatment group did not reach statistical significance (<i>P </i>for interaction = .06). Risk of SAE was higher among prefrail and frail men (prefrail vs robust AHR, 1.81; 95% CI, 1.48-2.23; frail vs robust AHR, 2.86; 95% CI, 2.21-3.69; linear<i>P</i> < .001); this association was similar across treatment groups (<i>P </i>for interaction = .76). <h3>Conclusions and Relevance</h3> These findings suggest that frailty is independently associated with greater risk of both clinical BPH progression and SAEs. Older frail men with BPH considering initiation of drug therapy should be counseled regarding their higher risk of progression despite combination therapy and their likelihood of experiencing SAEs regardless of treatment choice." @default.
• W3217437563 created "2021-12-06" @default.
• W3217437563 creator A5025363657 @default.
• W3217437563 creator A5027205779 @default.
• W3217437563 creator A5030832172 @default.
• W3217437563 creator A5041374470 @default.
• W3217437563 creator A5045222539 @default.
• W3217437563 creator A5047934585 @default.
• W3217437563 creator A5060170825 @default.
• W3217437563 creator A5063480864 @default.
• W3217437563 creator A5089985052 @default.
• W3217437563 date "2021-11-24" @default.
• W3217437563 modified "2023-10-03" @default.
• W3217437563 title "Assessment of Frailty and Association With Progression of Benign Prostatic Hyperplasia Symptoms and Serious Adverse Events Among Men Using Drug Therapy" @default.
• W3217437563 cites W1849315941 @default.
• W3217437563 cites W1915608460 @default.
• W3217437563 cites W1962103359 @default.
• W3217437563 cites W1963584997 @default.
• W3217437563 cites W1964370987 @default.
• W3217437563 cites W1987985119 @default.
• W3217437563 cites W2015452134 @default.
• W3217437563 cites W2030111210 @default.
• W3217437563 cites W2039361264 @default.
• W3217437563 cites W2045486511 @default.
• W3217437563 cites W2064798090 @default.
• W3217437563 cites W2083170911 @default.
• W3217437563 cites W2100819296 @default.
• W3217437563 cites W2101665942 @default.
• W3217437563 cites W2105669626 @default.
• W3217437563 cites W2106455438 @default.
• W3217437563 cites W2108688205 @default.
• W3217437563 cites W2117182317 @default.
• W3217437563 cites W2121759271 @default.
• W3217437563 cites W2128043538 @default.
• W3217437563 cites W2129700906 @default.
• W3217437563 cites W2139520621 @default.
• W3217437563 cites W2210162923 @default.
• W3217437563 cites W2295988053 @default.
• W3217437563 cites W2396140309 @default.
• W3217437563 cites W2461735466 @default.
• W3217437563 cites W2508328133 @default.
• W3217437563 cites W2513348288 @default.
• W3217437563 cites W2570781645 @default.
• W3217437563 cites W2615792377 @default.
• W3217437563 cites W2734509828 @default.
• W3217437563 cites W2752401946 @default.
• W3217437563 cites W2767958159 @default.
• W3217437563 cites W2782603231 @default.
• W3217437563 cites W2789886608 @default.
• W3217437563 cites W2803752334 @default.
• W3217437563 cites W2811157820 @default.
• W3217437563 cites W2890873793 @default.
• W3217437563 cites W2903235642 @default.
• W3217437563 cites W2939971450 @default.
• W3217437563 cites W2943513392 @default.
• W3217437563 cites W2944049715 @default.
• W3217437563 cites W2969233397 @default.
• W3217437563 cites W2969640399 @default.
• W3217437563 cites W2981151994 @default.
• W3217437563 cites W2981607211 @default.
• W3217437563 cites W2987509709 @default.
• W3217437563 cites W2990967293 @default.
• W3217437563 cites W2997183251 @default.
• W3217437563 cites W3015148487 @default.
• W3217437563 cites W3030634983 @default.
• W3217437563 cites W3080113240 @default.
• W3217437563 cites W3092138922 @default.
• W3217437563 cites W3119963873 @default.
• W3217437563 cites W3143060430 @default.
• W3217437563 cites W4232461194 @default.
• W3217437563 cites W4235336791 @default.
• W3217437563 cites W4243624943 @default.
• W3217437563 cites W4248419044 @default.
• W3217437563 cites W4253815515 @default.
• W3217437563 cites W4254024173 @default.
• W3217437563 doi "https://doi.org/10.1001/jamanetworkopen.2021.34427" @default.
• W3217437563 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34817584" @default.
• W3217437563 hasPublicationYear "2021" @default.
• W3217437563 type Work @default.
• W3217437563 sameAs 3217437563 @default.
• W3217437563 citedByCount "8" @default.
• W3217437563 countsByYear W32174375632022 @default.
• W3217437563 countsByYear W32174375632023 @default.
• W3217437563 crossrefType "journal-article" @default.
• W3217437563 hasAuthorship W3217437563A5025363657 @default.
• W3217437563 hasAuthorship W3217437563A5027205779 @default.
• W3217437563 hasAuthorship W3217437563A5030832172 @default.
• W3217437563 hasAuthorship W3217437563A5041374470 @default.
• W3217437563 hasAuthorship W3217437563A5045222539 @default.
• W3217437563 hasAuthorship W3217437563A5047934585 @default.
• W3217437563 hasAuthorship W3217437563A5060170825 @default.
• W3217437563 hasAuthorship W3217437563A5063480864 @default.
• W3217437563 hasAuthorship W3217437563A5089985052 @default.
• W3217437563 hasBestOaLocation W32174375631 @default.
• W3217437563 hasConcept C121608353 @default.
• W3217437563 hasConcept C126322002 @default.
• W3217437563 hasConcept C142724271 @default.
• W3217437563 hasConcept C197934379 @default.

• next